TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it will be presenting at the Sidoti Virtual Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the company’s RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company’s lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its first-in-human clinical trial. The presentation will be webcast and an archived recording will be made available in the Investors’ section of the TransCode Therapeutics website.
Related news for (RNAZ)
- Breaking News: MoBot’s Latest Update as of 07/23/25 12:00 PM
- MoBot’s Stock Market Highlights – 07/23/25 11:00 AM
- TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
- TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
- TransCode Therapeutics Announces 1-for-28 Reverse Stock Split